Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Randy Bennett"'
Autor:
T. Miller, Brooke Hayward, Barry A Singer, Sibyl Wray, Fernando Dangond, D Bandari, Randy Bennett, D Wynn
Publikováno v:
Multiple Sclerosis and Related Disorders. 2:45-56
In clinical studies, treatment with subcutaneous interferon beta-1a (IFNβ-1a) has been shown to reduce relapse rates and slow the progression of physical disability in patients with relapsing forms of multiple sclerosis (MS). A formulation of subcut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b750c0712f779f1aa60e6e901c1165c
https://doi.org/10.1016/j.msard.2012.07.005
https://doi.org/10.1016/j.msard.2012.07.005
Autor:
Khajak J. Ishak, Duygu Bozkaya, Ahmad Al-Sabbagh, D.M. Meletiche, Randy Bennett, Alexandra Ward, Shien Guo, Judith A. O'Brien
Publikováno v:
PharmacoEconomics. 27(1):39-53
Objective: The EVIDENCE trial concluded that administering high-dose/high-frequency subcutaneous (SC) interferon-beta-1a (IFNb1a) was more effective in preventing relapses among patients with relapsing multiple sclerosis (MS) than low-dose weekly int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::140fb48c96658505ecf3464b7096881d
http://PharmacoEconomics.adisonline.com/pt/re/pec/pdfhandler.00019053-200927010-00005.pdf
http://PharmacoEconomics.adisonline.com/pt/re/pec/pdfhandler.00019053-200927010-00005.pdf
Autor:
Randy Bennett, Christopher LaGanke, Barry A Singer, Daniel Bandari, John Huddlestone, Mark Cascione, Fernando Dangond
Publikováno v:
BMC Neurology, Vol 12, Iss 1, p 154 (2012)
BMC Neurology
BMC Neurology
Background In patients with relapsing–remitting multiple sclerosis (RRMS), subcutaneous (sc) interferon (IFN)β-1a and IFNβ-1b have been shown to reduce relapse rates. A formulation of IFNβ-1a has been produced without fetal bovine serum and with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd92104093d6f92edc6ce4da955bd141
http://www.biomedcentral.com/1471-2377/12/154
http://www.biomedcentral.com/1471-2377/12/154
Autor:
Donnie Funch, Jill Hillier, Randy Bennett, John D. Seeger, Ahmad Al-Sabbagh, Judy Wong, Heather Norman
Publikováno v:
Pharmacoepidemiology and Drug Safety.
Purpose Mitoxantrone was approved for treatment of multiple sclerosis (MS) in October 2000. Monitoring and dosing guidelines in the product labeling accompanying this indication include blood counts, liver function, and pregnancy tests at each admini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c60c88e48626825a09b7c89da3c3f81e
https://doi.org/10.1002/pds.1918
https://doi.org/10.1002/pds.1918
Autor:
Randy Bennett, Daniel Mikol, Ahmad Al-Sabbagh, Bruce Hughes, Vamil Divan, Mark S. Freedman, Nicole LaVallee, Brian Cuffel
Publikováno v:
European neurology. 60(1)
The treatment of relapsing-remitting multiple sclerosis (RRMS) has become more effective over the last decade with the advent of the currently available disease-modifying therapies (DMTs). Pivotal clinical studies differ in many characteristics, such
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85126c0e515e31c1a5014bc1a98f3c19
https://pubmed.ncbi.nlm.nih.gov/18437041
https://pubmed.ncbi.nlm.nih.gov/18437041
Autor:
Jim D. Meador, Mariya Nagatkina, Sam X. Sun, Tomoyuki Enomoto, Denise Gum, Randy Bennett, Doug Holmes, Rama Puligadda
Publikováno v:
SPIE Proceedings.
This paper presents our progress in developing spin-on, thermosetting hardmasks and bottom antireflective coatings (BARCs) for 193-nm trilayer usage. Binder materials that were used in preparing the silicon-containing hardmasks include polymers with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75a429471896b3adc5788c1126b69321
https://doi.org/10.1117/12.533539
https://doi.org/10.1117/12.533539
Autor:
Doug Holmes, William L. DiMenna, Jim D. Meador, Mariya Nagatkina, Tony D. Flaim, Randy Bennett, Ichiro Kobayashi, Michael D. Rich
Publikováno v:
Advances in Resist Technology and Processing XX.
This paper highlights the performance of new materials that have been developed for use in 193-nm trilayer microlithography. The products are embedded etch masking layers (EMLs) and bottom antireflective coatings (BARCs). Both coatings are spin appli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::845eaf22a0d7c4005d0f2913b71aca87
https://doi.org/10.1117/12.485082
https://doi.org/10.1117/12.485082
Autor:
Randy Bennett, S. Kirzinger, Barry A Singer, A. AL-Sabbagh, Fernando Dangond, Douglas Jeffery
Publikováno v:
Journal of the Neurological Sciences. 285:S204
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::237a1cda9cbc0df8361eb861ddc47fcd
https://doi.org/10.1016/s0022-510x(09)70781-6
https://doi.org/10.1016/s0022-510x(09)70781-6
Publikováno v:
Archives of Neurology. 62:1681
Background African Americans (AAs) with multiple sclerosis (MS) seem to have a more severe disease course than white Americans (WAs). To our knowledge, it is not known to what extent treatment with interferon beta-1a will effect the MS disease course
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82917dbf34e40b7101f28ca6810f789d
https://doi.org/10.1001/archneur.62.11.1681
https://doi.org/10.1001/archneur.62.11.1681
Publikováno v:
BMC Neurology
BMC Neurology, Vol 8, Iss 1, p 11 (2008)
BMC Neurology, Vol 8, Iss 1, p 11 (2008)
Background: The EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study was an international, randomized, open-label, assessor-blinded, parallel-group study assessing the efficacy and tolerability of interf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::368b2789c5da51342848da6c2c8584ec